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Changes in expression and secretion levels of cystatin C (CysC) in the brain in various
neurological disorders and in animal models of neurodegeneration underscore a role for
CysC in these conditions. A polymorphism in the CysC gene (CST3) is linked to increased
risk for Alzheimer’s disease (AD). AD pathology is characterized by deposition of oligomeric
and fibrillar forms of amyloid β (Aβ) in the neuropil and cerebral vessel walls, neurofibrillary
tangles composed mainly of hyperphosphorylated tau, and neurodegeneration. The
implication of CysC in AD was initially suggested by its co-localization with Aβ in
amyloid-laden vascular walls, and in senile plaque cores of amyloid in the brains of patients
with AD, Down’s syndrome, hereditary cerebral hemorrhage with amyloidosis, Dutch type
(HCHWA-D), and cerebral infarction. CysC also co-localizes with Aβ amyloid deposits
in the brains of non-demented aged individuals. Multiple lines of research show that
CysC plays protective roles in AD. In vitro studies have shown that CysC binds Aβ and
inhibits Aβ oligomerization and fibril formation. In vivo results from the brains and plasma
of Aβ-depositing transgenic mice confirmed the association of CysC with the soluble,
non-pathological form of Aβ and the inhibition of Aβ plaques formation. The association of
CysC with Aβwas also found in brain and in cerebrospinal fluid (CSF) from AD patients and
non-demented control individuals. Moreover, in vitro results showed that CysC protects
neuronal cells from a variety of insults that may cause cell death, including cell death
induced by oligomeric and fibrillar Aβ. These data suggest that the reduced levels of CysC
manifested in AD contribute to increased neuronal vulnerability and impaired neuronal
ability to prevent neurodegeneration. This review elaborates on the neuroprotective roles
of CysC in AD and the clinical relevance of this protein as a therapeutic agent.
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INTRODUCTION
CysC also known as γ-trace, is a basic protein (Hochwald et al.,
1967), originally identified in human CSF and subsequently, also
found in all other mammalian body fluids and tissues (Bobek
and Levine, 1992; Turk et al., 2008). CysC is highly abundant
in brain tissue (Hakansson et al., 1996), expressed by neurons,
astrocytes, and microglial cells in the brains of different species
(Yasuhara et al., 1993; Palm et al., 1995; Miyake et al., 1996). CysC
plays a variety of biological roles, ranging from anti-viral and
anti-bacterial properties (Bobek and Levine, 1992), bone resorp-
tion (Lerner and Grubb, 1992), tumor metastasis (Huh et al.,
1999; Taupin et al., 2000), modulation of inflammatory responses
(Warfel et al., 1987; Bobek and Levine, 1992), cell proliferation
and growth (Sun, 1989; Tavera et al., 1992), and astrocytic differ-
entiation duringmouse brain development (Kumada et al., 2004).
Involvement of CysC has been shown in various diseases rang-
ing from cancer to neurodegenerative disorders. Multiple studies
have demonstrated changes in CysC concentrations in serum
associated with a variety of conditions, such as chronic kidney
disease, urinary infection, cancer, hypertension, cardiovascular
disease, rheumatoid arthritis, glucocorticoid treatment, thyroid
function, and aging (reviewed in Filler et al., 2005). CysC concen-
tration in specific tissues and body fluids can serve as a marker
for a variety of diseases, disease progression, and the effect of
therapy.
CysC is also implicated in the processes of neuronal degenera-
tion and repair of the nervous system (reviewed in Gauthier et al.,
2011). CysC was originally identified as an inhibitor of cysteine
proteases such as cathepsins required for housekeeping function
during protein turnover (Turk et al., 2000). Imbalance between
active proteases and their endogenous inhibitors may lead to
uncontrolled proteolysis, which has been associated with different
neurological diseases (Nakamura et al., 1991). The involvement of
proteases and their inhibitors in the processes of neuronal degen-
eration and repair of the nervous system is reviewed in (Tizon and
Levy, 2006).
The majority of CysC in the CSF is produced by the choroid
plexus (Tu et al., 1992). CysC CSF levels in normal brain were
found to be five times higher than plasma levels suggesting a
potential physiological role of CysC in the brain (Grubb, 1992).
Alterations in CysC levels in the CSF in neurodegenerative dis-
eases have been documented (Pasinetti et al., 2006; Mares et al.,
2009; Mori et al., 2009; Tsuji-Akimoto et al., 2009; Yang et al.,
2009; Maetzler et al., 2010). For example, CysC has shown a
great diagnostic potential as a biomarker for Amyotropic Lateral
Sclerosis (ALS), a fatal neuromuscular disease characterized by
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progressive motor neuron degeneration (Wilson et al., 2010).
CysC levels in the CSF of ALS patients were significantly reduced
as compared to healthy controls (Pasinetti et al., 2006; Tsuji-
Akimoto et al., 2009; Wilson et al., 2010). In addition, the
direction of the longitudinal change in CSF CysC levels corre-
lated with the rate of ALS disease progression, and initial CSF
CysC levels were predictive of patient survival, suggesting that
CysC may function as a surrogate marker of disease progres-
sion and survival (Wilson et al., 2010). CysC is also linked to
ALS histopathologically, as it is one of only two known proteins
that localize to Bunina bodies, small intraneuronal inclusions
contained in degenerating motor neurons, which are a specific
neuropathologic feature of ALS (Okamoto et al., 2008). Similarly,
it was shown that CysC levels in the CSF of AD patients are lower
compared to non-demented individuals (Simonsen et al., 2007;
Hansson et al., 2009). Furthermore, specific neuronal cell pop-
ulations in the brains of patients with AD showed an enhanced
CysC expression (Deng et al., 2001; Levy et al., 2001). Changes in
the levels of CysC in the CSF and brain in various neurodegen-
erative diseases suggest important roles for the secreted protein
in these disorders. In support of such a role, CysC level dysregu-
lation was also observed in animal models of neurodegenerative
conditions caused by facial nerve axotomy (Miyake et al., 1996),
noxious input to the sensory spinal cord (Yang et al., 2001),
perforant path transections (Ying et al., 2002), hypophysectomy
(Katakai et al., 1997), transient forebrain ischemia (Palm et al.,
1995; Ishimaru et al., 1996), photothrombotic stroke (Pirttila
and Pitkanen, 2006), and induction of epilepsy (Aronica et al.,
2001; Hendriksen et al., 2001; Lukasiuk et al., 2002). Augmented
CysC expression in the neurodegenerative states puts forward
two conflicting theories whether enhanced CysC expression is
causing or further exacerbating already initiated neurodegenera-
tive changes or, alternatively, it is an endogenous neuroprotective
response to the disease (reviewed in Gauthier et al., 2011). This
review focuses on the roles of CysC in the pathological processes
of AD.
CysC AND ALZHEIMER’S DISEASE
AD pathology is characterized by formation of amyloid deposits
in the brain composed mainly of Aβ, a processing product of the
amyloid β precursor protein (APP), aggregation of neurofibril-
lary tangles composed mainly of hyperphosphorylated tau, loss
of neurons with accelerated atrophy of specific brain areas and
decreased synapse number in surviving neurons. While it was
demonstrated that fibrillar Aβ plays a central role in neurotoxi-
city in AD brains (for review see Butterfield and Boyd-Kimball,
2004), both in vitro and in vivo reports describe a potent neu-
rotoxic activity for soluble, nonfibrillar, oligomeric assemblies of
Aβ (for reviews see Klein et al., 2001; Walsh and Selkoe, 2004).
In this section, we discuss the involvement of CysC in AD as
suggested by immunohistochemical, genetic, and biochemical
studies.
CysC CO-DEPOSITION WITH AMYLOID β
The involvement of cystatins in AD was originally suggested due
to their co-localization with amyloid plaques. CysC was the first
cystatin found co-localized with Aβ in amyloid-laden vascular
walls, and in senile plaque cores of amyloid in brains of patients
with AD, Down’s syndrome, HCHWA-D, intracranial hemor-
rhage, cerebral infarction, and of elderly subjects without any
neurological disorder (Maruyama et al., 1990; Vinters et al., 1990;
Itoh et al., 1993; Haan et al., 1994; Levy et al., 2001). Abundant
cystatin A (CysA) and cystatin B (CysB), also called stefin B, were
demonstrated in senile plaques in the brain of AD patients (Ii
et al., 1993; Bernstein et al., 1994).
The deposition of fibrillar protein aggregates in the walls of
arteries, arterioles, and sometimes capillaries and veins of the
central nervous system is known as cerebral amyloid angiopa-
thy (CAA) (Nagai et al., 2008). Hereditary cerebral hemorrhage
with amyloidosis, Icelandic type (HCHWA-I) (Arnason, 1935;
Gudmundsson et al., 1972), also called hereditary cystatin C
amyloid angiopathy (HCCAA; Olafsson et al., 1996), is an auto-
somal dominant form of CAA. Amyloid deposition in cerebral
and spinal arteries and arterioles of HCHWA-I patients leads to
recurrent hemorrhagic strokes causing serious brain damage and
eventually fatal stroke (Gudmundsson et al., 1972). The amy-
loid deposited is composed mainly of a Leu68Gln variant of
CysC (Cohen et al., 1983; Ghiso et al., 1986; Palsdottir et al.,
1988; Levy et al., 1989; Abrahamson et al., 1990). A heterozy-
gous point mutation, identical to that found in the CST3 gene
of these patients, was also identified in a Croatian man with CAA
and intracerebral hemorrhage (Graffagnino et al., 1995). Thus,
sporadic CAA in some patients may be associated with muta-
tions in the CST3 gene (Graffagnino et al., 1995; McCarron et al.,
2000).
Amyloid β usually accumulates both in cerebral blood ves-
sels and in brain parenchyma as amyloid plaques. However, in
some cases Aβ deposits predominantly in the cerebral vascula-
ture (Vinters, 2001). The factors leading to vascular rather than
parenchymal amyloid deposition are unknown and it is unclear
when CAA leads to hemorrhage. A role for CysC in CAA-related
hemorrhage is implicated from immunohistochemical studies
that revealed co-localization of CysC and Aβ in amyloid-laden
vascular walls (Maruyama et al., 1990; Vinters et al., 1990; Itoh
et al., 1993; Haan et al., 1994). It was reported that only patients
showing co-localization of CysC and Aβ immunoreactivity in
their diseased cerebral vessels suffered fatal subcortical hemor-
rhages (Maruyama et al., 1990). The degree of cerebrovascular
amyloid deposition in these patients was also greater than in
patients without cerebral hemorrhages. Studies were conducted
to find out whether CysC exists as amyloid fibrils or as unpoly-
merized CysC absorbed onto or trapped within the bundles of
Aβ amyloid fibrils. ELISA analysis of crude amyloid fibrils iso-
lated from cerebral blood vessels of one patient revealed that
CysC and Aβ have been included at the ratio of about 1:100
(Nagai et al., 1998). In another case of sporadic CAA, isola-
tion and chemical analysis of amyloid fibril proteins from lep-
tomeningeal vessels revealed that while Aβ was fibrillar, CysC
was soluble (Maruyama et al., 1992). It has been suggested that
CysC deposition occurs secondarily to Aβ deposition and may
increase the predisposition to cerebral hemorrhages (Itoh et al.,
1993).
CysC also co-localizes with Aβ deposits in the brains of ani-
mal models of cerebral amyloidosis. Co-localization of Aβ and
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CysC was demonstrated in vascular and parenchymal deposits in
the brains of aged rhesus monkeys and in vascular amyloid in
brains of aged squirrel monkeys (Wei et al., 1996). Non-human
primates are good models to study cerebral changes that occur
through aging. Neuropathologies characteristic of AD and nor-
mal aging in humans were also found in senescent non-human
primates (Wisniewski and Terry, 1973; Walker et al., 1990; Price
et al., 1994). In aged rhesus monkeys (Macaca mulatta), amy-
loid deposition predominates in senile plaques with relatively
minor vascular involvement. However, cerebrovascular deposits
in aged squirrel monkeys (Saimiri sciureus), usually are more
conspicuous than senile plaques (Walker et al., 1990). Sequence
analysis of rhesus and squirrel monkey CysC cDNA revealed that
squirrel monkey has Met at position 68, which is Leu in the rhe-
sus and wild-type human CysC and Gln in HCHWA-I patients
(Wei et al., 1996). An additional difference between squirrel and
rhesus monkeys in CysC sequence was found at position 10, a
residue that was shown to affect the specificity of the inhibitor
for different cysteine proteases (Lindahl et al., 1994). The species-
specific CysC sequences in humans, rhesus, and squirrel monkeys
may be responsible for the variability of the amyloid deposits
observed.
In order to elucidate the role of increased expression of this
protein in vivo, CysC transgenic mice were generated (Pawlik
et al., 2004). These mice express either human wild-type or the
Leu68Gln variant CysC genes under the transcriptional con-
trol of its own promoter (Levy et al., 1989), overexpressing the
transgene along with its endogenous counterpart in the appro-
priate tissues (Pawlik et al., 2004). Lines of mice expressing
various levels of the transgene in the brain were selected. All
selected lines had very high concentrations of the transgene in
the blood. None of the mice had amyloid deposits either in
the vessel walls or in the neuropil. Neuropathological exami-
nation of dead or ailing aged transgenic mice revealed some
mice with cerebral or subarachnoid hemorrhages (Pawlik et al.,
2002). Conversely, no hemorrhages were observed in their non-
transgenic siblings. These data demonstrate that elevated brain
and/or blood levels of CysC can cause hemorrhagic strokes in
the absence of vascular amyloid deposits. It has been shown
that the risk of cerebral hemorrhage in the brains of aged indi-
viduals and AD patients increases when high levels of CysC
are present in cerebrovascular Aβ deposits. These findings sug-
gest that binding of CysC to Aβ in the vasculature, resulting in
local accumulation of the protease inhibitor, may contribute to
hemorrhages.
CysC also co-localizes with Aβ deposits in the parenchyma and
vasculature in brains of transgenic mice overexpressing human
APP (Levy et al., 2001; Steinhoff et al., 2001). A striking increase
in CAA with aging was found in the APP transgenic mouse
line APP23 (Winkler et al., 2001). Antibodies to CysC revealed
appreciable staining of cerebrovascular amyloid in these mice.
Similar to CysC staining of Aβ deposits in human brains, the CysC
immunoreactivity was restricted to a subpopulation of amyloid-
laden vessels and was clearly less intense than Aβ staining (Levy
et al., 2001; Steinhoff et al., 2001; Winkler et al., 2001).
Wild-type CysC co-localization with amyloid, other than Aβ,
was observed in a variety of disorders, such as hereditary gelsolin
amyloidosis (familial amyloidosis, Finnish type; Kiuru et al., 1999;
Kiuru-Enari et al., 2002) and familial CAA, British type (Ghiso
et al., 1995). Thus, CysC may play a role in CAA and hemorrhage
in a variety of diseases that involve deposition of heterogeneous
types of amyloid proteins.
INTRACELLULAR CO-LOCALIZATION OF CysC WITH Aβ IN THE BRAIN
Immunohistochemical analyses have shown intense CysC
immunoreactive neurons and activated glia in the cerebral
cortex of some aged human cases and of all AD patients
(Yasuhara et al., 1993; Deng et al., 2001). High neuronal
staining of CysC in AD brains was primarily limited to pyra-
midal neurons in cortical layers III and V (Deng et al., 2001;
Levy et al., 2001). The regional distribution of CysC neuronal
immunostaining duplicated the pattern of neuronal suscep-
tibility in AD brains: the strongest staining was found in the
entorhinal cortex, in the hippocampus, and in the temporal
cortex; fewer pyramidal neurons were stained in the frontal,
parietal, and occipital lobes (Deng et al., 2001). Using an
end-specific antibody to the carboxyl-terminus of Aβ42, intra-
cellular immunoreactivity was observed in the same neuronal
subpopulation (Levy et al., 2001). These data showed that
Aβ42 accumulates in a specific population of pyramidal neu-
rons in the brain, the same cell type in which CysC is highly
expressed.
LOW CONCENTRATION OF CysC IN CSF AND PLASMA OF AD PATIENTS
Low levels of serum CysC precede clinically manifested AD in
elderly men free of dementia at baseline and may be a marker
of future risk of AD (Sundelof et al., 2008). Clinically diag-
nosed AD patients also showed a reduction in the CSF levels of
CysC compared to controls (Hansson et al., 2009). Interestingly,
CysC levels were positively correlated with both tau and Aβ42
levels in the CSF, independent of age, gender, and apolipopro-
tein E (APOE) genotype (Sundelof et al., 2010). Therefore, it
was suggested to measure the change in CysC CSF levels as
a biomarker for AD diagnosis (Simonsen et al., 2007; Mares
et al., 2009; Zellner et al., 2009; Ndjole et al., 2010; Sundelof
et al., 2010; Craig-Schapiro et al., 2011; Perrin et al., 2011).
Moreover, analysis of CysC levels in plasma revealed a signifi-
cant tendency of conversion from mild cognitive impairment to
dementia in subjects with CysC levels below the median (CysC
lower than 1067 ng/ml; Ghidoni et al., 2010). A large proportion
of demented Lewy body disease patients have AD-like pathol-
ogy, in particular Aβ plaques. Demented Lewy body disease
patients also showed decreased CSF CysC levels (Maetzler et al.,
2010).
LINKAGE OF CysC GENE POLYMORPHISM WITH AD
Studies were conducted to determine whether the association of
CysC with AD could be identified at the genetic level. The CST3
gene, localized on chromosome 20 (Abrahamson et al., 1989;
Saitoh et al., 1989), has three genetically linked base substitu-
tions in the 3′ region (Balbin and Abrahamson, 1991; Balbin
et al., 1993). A G73A transition in exon 1 results in Ala/Thr
variation in the coding region of CST3, within the signal pep-
tide. While the allele containing Ala at that position was called
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the A allele, the one containing Thr in the same position was
called B allele. Several studies have linked CST3 gene polymor-
phisms with an increased risk of developing AD (Crawford et al.,
2000; Finckh et al., 2000; Beyer et al., 2001; Olson et al., 2002;
Lin et al., 2003; Goddard et al., 2004; Cathcart et al., 2005;
Bertram et al., 2007) and a possible interaction with APOE
genotype was noted. However, some studies have failed to show
an association between CST3 and AD in a German cohort
(Dodel et al., 2002), a Dutch sample with early onset AD (Roks
et al., 2001), Japanese AD patients (Maruyama et al., 2001), a
Finnish population (Helisalmi et al., 2009), and in early onset
AD families (Parfitt et al., 1993). Other studies found a con-
nection between the CST3 polymorphism and AD in Caucasian
populations, but not in Asian populations (Hua et al., 2012),
including Chinese (Wang et al., 2008). Over-all meta-analyses
using this polymorphism have reported CST3 as a susceptibility
gene for AD. For update on the linkage of the CST3 polymor-
phism with AD, see the Alzgene Internet site of the Alzheimer
Research Forum (http://www.alzforum.org/res/com/gen/alzgene/
geneoverview.asp?geneid=66).
Some groups have shown that the A allele of CST3may be crit-
ical for the development of AD while others have held B allele
responsible for that. A multicentric AD population was geneti-
cally studied by age at onset and it was found that A allele of CST3
has an age related increased influence on onset of AD (Crawford
et al., 2000). A significant interaction between the homozygous
A genotype of CST3 and age of onset of AD was found, such
that in the over 80 years age group this genotype was responsi-
ble for a twofold increased risk for the disease. This interaction
was independent of the APOE genotype (Crawford et al., 2000).
Another study of large European and American populations, with
mean age at onset of 73.1 and 75.0 for AD and controls, respec-
tively, showed linkage between the B allele and late onset AD
with no synergistic association with APOE allele (Finckh et al.,
2000). A synergistic association between the CST3 and APOE
ε4 alleles was found in a Spanish sample. The CST3 B allele
caused a threefold elevated risk of AD before age 70 and there
was an eightfold increase in risk for APOE ε4 carriers with this
allele (Beyer et al., 2001). In another genetic study the combi-
nation of one or two CST3 B alleles and APOE ε4 carried a
14-fold increased risk for men and 16-fold for women. These
risks apply to a shift in risk from ages 65 and older to younger
ages (Cathcart et al., 2005). The attempt to determine the associ-
ation between CST3 polymorphism and AD or vascular dementia
resulted in the associations between CST3 B genotype and AD
patients older than 75, or vascular dementia patients younger
than 75 years. A synergistic association of CST3 and APOE ε4
alleles was observed in predicting vascular dementia patients (Lin
et al., 2003).
The amino acid exchange from Ala to Thr at the –2 position
for signal peptide cleavage alters the hydrophobicity profile of
the signal sequence (Finckh et al., 2000), resulting in a less effi-
cient cleavage of the signal peptide and thus a reduced secretion
of CysC (Benussi et al., 2003). The CST3 gene G73A poly-
morphism functionally affects CysC plasma levels (Noto et al.,
2005) and CysC CSF levels (Maetzler et al., 2010; Yamamoto-
Watanabe et al., 2010). Maetzler and colleagues (Maetzler et al.,
2010) showed that the BB genotype of the CST3 gene is associ-
ated with reduced CSF CysC levels in patients with Lewy body
disease with dementia. Furthermore, a study of the targeting
of the Thr haplotype in cultured retinal pigment epithelial and
HeLa cells have shown that a proportion of the Thr protein
undergoes incorrect trafficking. In contrast to the Ala haplo-
type that is targeted to the Golgi apparatus, the Thr variant was
associated primarily with mitochondria, resulting in a substan-
tial reduction in the efficiency of targeting CysC for secretion
(Paraoan et al., 2004). A multicentric electroencephalographic
(EEG) study analyzed the effects of CST3 haplotypes on rest-
ing cortical rhythmicity in subjects with AD and mild cognitive
impairment. A relationship between the CST3 Thr haplotype and
global neurophysiological phenotype (i.e., cortical delta and alpha
rhythmicity) was found. While APOE ε4 affects EEG rhythms
in AD (Lehtovirta et al., 1996, 2000; Jelic et al., 1997), the
effects of CST3 polymorphism were independent of APOE ε4
co-presence (Babiloni et al., 2006). A decreased CysC secretion
associated with a polymorphism found in the CysC gene, puts
forward a mechanism for the increased-risk of late-onset spo-
radic AD conferred by this polymorphism and suggests that
reduced CysC brain concentration may be associated with the
disease.
ALTERED CysC TRAFFICKING AND FAMILIAL AD
Mutations in the presenilin 1 and presenilin 2 genes account
for the majority of familial AD (FAD) cases. Two of the muta-
tions in the presenilin 2 gene that are linked to FAD (PS2 M239I
and T122R) alter CysC trafficking in mouse primary neurons
and cause reduced CysC secretion (Ghidoni et al., 2007). The
primary structure of CysC is indicative of a secreted protein
and accordingly, it was demonstrated that most of the CysC
is targeted extracellularly via the secretory pathway (Wei et al.,
1998; Paraoan et al., 2001). Moreover, it was recently shown
that CysC is also secreted in association with exosomes (Ghidoni
et al., 2011). Full-length APP and APP processing products,
including Aβ are also released in association with exosomes.
Over-expression of presenilin 2 with the FAD-associated muta-
tions (PS2 M239I and PS2 T122R) resulted in decreased levels
of CysC within exosomes (Ghidoni et al., 2011). Assuming a
protective role for CysC, as described below, the reduction in
CysC levels may represent the molecular factor responsible for
the increased risk of AD in FAD patients, the carriers of these
mutations.
NEUROPROTECTION BY CysC IN AD
Intense CysC immunoreactivity was observed in specific neu-
ronal populations in the cerebral cortex of some aged human
cases and of all AD patients (Yasuhara et al., 1993; Deng
et al., 2001; Levy et al., 2001). Enhanced CysC expression in
specific cell populations is not limited to AD but was also
observed in other neurodegenerative conditions, such as epilepsy,
ischemia, and progressive myoclonus epilepsy (Palm et al., 1995;
Ishimaru et al., 1996; Aronica et al., 2001; Hendriksen et al.,
2001; Lukasiuk et al., 2002; Kaur et al., 2010). Contradictory
conclusions were reached from multiple studies, suggesting
that increased CysC cellular expression in the brain is either
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associated with the neurodegenerative process, or alternatively
is part of a neuroprotective response aimed at prevention of
neurodegeneration. In this section of the review we provide
a description of different neuroprotective mechanisms acti-
vated by CysC. We hypothesize that reduced secretion of CysC
into extracellular body fluids can hamper the ability of the
brain to prevent neurodegeneration in various pathological
conditions.
Protection by inhibition of cysteine proteases
In vitro experiments have shown that CysC inhibits cathep-
sins B, H, K, L, and S (for review see Bernstein et al.,
1996) and is inactivated by proteolytic degradation by
cathepsin D (Abrahamson et al., 1991; Lenarcic et al., 1991).
Neuropathological observations suggest an association between
CysC and cathepsins B and D in AD (Deng et al., 2001).
Pyramidal neurons in layers III and V in the cortex of AD
patients have displayed a quantitative increase in cathepsin D
immunoreactivity (Cataldo et al., 1995), the same neuronal
population that show increased CysC expression (Deng et al.,
2001; Levy et al., 2001). Lysosomal cathepsins are involved in
neuronal cell death (Cataldo and Nixon, 1990). Intense cyto-
plasmic labeling of cathepsin B was detected when neurons had
become morphologically altered with obvious shrinkage of the
cytoplasm (Hill et al., 1997). Enhanced expression of several
cathepsins has been documented in response to injuries, similar
to those inducing CysC expression upregulation, such as in
transient ischemia (Nitatori et al., 1995; Yamashima et al., 1998),
and inhibitors of cathepsins B and L reduce neuronal damage
in the hippocampus after ischemia (Tsuchiya et al., 1999). An
imbalance in the expression of cathepsins and their inhibitors
may cause or exacerbate existing neuropathological changes and
increased localizes CysC expression may represent an attempt to
curb the cathepsin activity.
The in vivo role of CysC as an inhibitor was observed by
deletion of CysC in knockout mice, resulting in an increased
cathepsin B activity (Sun et al., 2008). Another in vivo study
has demonstrated that CysC can mediate neuroprotection by
inhibition of cysteine proteases. A mouse model of an inherited
neurodegenerative disorder, the progressive myoclonic epilepsy,
has been generated by knocking-out the CysB gene (Pennacchio
et al., 1998). CysB deficiency in these mice results in increased
cathepsins activity (Kaur et al., 2010). CysC overexpression in
CysB knockout mice decreased cathepsin B and D activities in
the brain (Kaur et al., 2010). It was demonstrated that clinical
symptoms and neuropathologies, including deficient motor coor-
dination, cerebellar atrophy, neuronal loss in the cerebellum and
cerebral cortex, and gliosis caused by CysB deficiency, are res-
cued by CysC overexpression (Kaur et al., 2010). These data show
that CysC partially prevents neurodegeneration in CysB knockout
mice through inhibition of cathepsins activity.
Protection by induction of autophagy
An in vitro study of the effect of CysC on cells of neuronal origin
under neurotoxic stimuli has shown that CysC protects neuronal
cells from death by a mechanism that does not require cathep-
sin inhibition (Tizon et al., 2010b). Exogenously applied human
CysC protected neuronal cells from death in a concentration
dependent manner. Moreover, primary cortical neurons isolated
from the brains of CysC overexpressing transgenic mice (Pawlik
et al., 2004) were protected from spontaneous death induced by
culturing and from B27-supplement-deprivation, and cells iso-
lated from CysC knockout mice (Huh et al., 1999) were more
sensitive to in vitro toxicity compared to cells isolated from brains
of wild-type mice (Tizon et al., 2010b). Using multiple methods,
it was demonstrated that CysC induces autophagy in cells under
basal conditions, and enhances the autophagic activation in cells
exposed to nutritional deprivation and oxidative stress (Tizon
et al., 2010b). The autophagic pathway consists of sequestration
and turnover of organelles and cytoplasm in autophagic vacuoles
that following maturation fuse with lysosomes, leading to degra-
dation of their content. CysC induces a fully functional autophagy
via the mTOR pathway that includes competent proteolytic clear-
ance of autophagy substrates by lysosomes (Tizon et al., 2010b).
Enhanced lysosomal turnover can protect against neurodegen-
eration and CysC can serve to modulate the efficiency of the
autophagic pathway. It remains to be demonstrated that CysC
induces autophagy in vivo as a protective mechanism in brain
injury and in neurodegenerative disorders, such as AD.
Protection by inhibition of Aβ oligomerization and amyloid fibril
formation
The co-localization of CysC with Aβ in parenchymal and vascular
amyloid deposits reflects the involvement of CysC in amyloidoge-
nesis, therefore, the association of CysC with Aβ was determined
by Western blot analysis of immunoprecipitated cell lysate or
medium proteins, revealing binding of CysC to full-length APP
and to secreted soluble APP (Sastre et al., 2004). Deletion mutants
of APP localized the CysC binding site to the Aβ region within
APP. CysC association with APP resulted in increased secre-
tion of soluble APP but did not affect the levels of secreted Aβ
both in vitro (Sastre et al., 2004) and in vivo in transgenic mice
expressing the human CysC gene (Pawlik et al., 2004). The asso-
ciation of CysC with APP was confirmed using a method for
the in vivo mapping of protein interactions in intact mouse tis-
sue (Bai et al., 2008). CysC does not bind only to Aβ sequences
within APP, but also to the peptide itself (Sastre et al., 2004).
Analysis of the association of CysC and Aβ demonstrated a
specific, saturable and high affinity binding between CysC and
both Aβ1−42 and Aβ1−40 (Sastre et al., 2004). Most importantly,
CysC association with Aβ resulted in a concentration depen-
dent inhibition of Aβ amyloid fibril formation (Sastre et al.,
2004). In vitro studies also demonstrated that CysC association
with Aβ inhibits Aβ oligomerization (Selenica et al., 2007; Tizon
et al., 2010a). A structural model of the human CysC/Aβ complex
using a combination of selective proteolytic excision and high-
resolution mass spectrometry identified a specific C-terminal
epitope (residues 101–117) as the Aβ-binding region within CysC
(Juszczyk et al., 2009).
The anti-amyloidogenic role of CysC was demonstrated in
vivo in Aβ depositing APP transgenic mice overexpressing human
CysC. Several lines of transgenic mice, expressing human CysC
either under control sequences of the human CysC gene (Mi
et al., 2007), or specifically in cerebral neurons (Kaeser et al.,
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2007), were crossbred with mice overexpressing human APP.
CysC bound to the soluble, non-pathological form of Aβ in the
brains and plasma of these mice and inhibited the aggregation
and deposition of Aβ plaques in the brain (Kaeser et al., 2007; Mi
et al., 2007). However, deletion of CysC in knockoutmice resulted
in enhanced Aβ degradation (Sun et al., 2008). Unlike a complete
deletion of CysC, reduced or enhanced levels of CysC expression
affect the aggregation of Aβ, not Aβ levels (Kaeser et al., 2007; Mi
et al., 2007).
Investigation of the binding between Aβ and CysC in
human central nervous system was conducted by co-
immunoprecipitation of CysC and Aβ in brain and CSF
from AD patients and controls (Mi et al., 2009). Sequential
centrifugation of brain homogenates was used to identify that
the cellular fraction contains Aβ/CysC complexes. While CysC
binding to soluble Aβ was observed in AD patients and con-
trols, an SDS-resistant, stable CysC/Aβ complex was detected
exclusively in brains of neuropathologically normal controls,
but not in AD cases. The association of CysC with Aβ in brain
from control individuals and in CSF revealed an interaction of
these two polypeptides in their soluble form (Mi et al., 2009).
The association between Aβ and CysC was shown to prevent
Aβ accumulation and fibrillogenesis in experimental systems,
arguing that CysC plays a protective role in the pathogenesis of
AD in humans and explains why a decrease in CysC concentra-
tion caused by the CST3 polymorphism or by specific presenilin
2 mutations, can lead to the development of the disease. In
addition to its anti-amyloidogenic property, CysC directly pro-
tects neuronal cells from Aβ toxicity. The extracellular addition
of human CysC together with preformed either oligomeric or
fibrillar Aβ to cultured primary hippocampal neurons and to a
neuronal cell line increased cell survival (Tizon et al., 2010a). The
data obtained show that subtle modifications in CysC expression
levels in the central nervous system, or possibly in the periphery,
affect amyloid deposition and protect from the toxicity of
aggregated Aβ.
Aβ interacts not only with CysC (Sastre et al., 2004), but also
with CysB (Skerget et al., 2010; Zerovnik et al., 2010). It was
shown that CysB binding to Aβ is oligomer specific and that
the dimers and tetramers of CysB inhibit Aβ fibril formation
(Skerget et al., 2010). Aβ interaction with amyloid proteins is
not restricted to CysC, but include transthyretin (Schwarzman
et al., 1994, 2004; Choi et al., 2007; Buxbaum et al., 2008), gelsolin
(Chauhan et al., 1999), α2-macroglobulin (Kuo et al., 2000), and
crystallin-αB (Wilhelmus et al., 2006). The interaction between
the amyloidogenic proteins and Aβ inhibits Aβ fibril formation
(Matsuoka et al., 2003; Sastre et al., 2004; Wilhelmus et al., 2006;
Kaeser et al., 2007; Mi et al., 2007; Skerget et al., 2010). Wilhelmus
et al. (2007) suggested that “amateur” chaperones that co-localize
with the pathological lesions of AD, such as apolipoproteins and
heparan sulfate proteoglycans, bind amyloidogenic proteins and
may be involved in conformational changes of Aβ and in the
clearance of Aβ from the brain via phagocytosis or active trans-
port across the blood-brain barrier. Similarly, interaction between
amyloidogenic proteins results in inhibition of amyloid formation
and, therefore, has a neuroprotective function in diseases such
as AD.
Protection by neurogenesis
CysC can also regulate cell proliferation (Sun, 1989; Tavera et al.,
1992). In rats undergoing acute hippocampal injury or sta-
tus epilepticus-induced epileptogenesis, the expression of CysC
mRNA and protein are increased in the hippocampus and in
the dentate gyrus (Aronica et al., 2001; Hendriksen et al., 2001;
Lukasiuk et al., 2002). The time of increased CysC expression
was shown to be matching the time of prominent neurogenesis
(Parent et al., 1997; Nairismagi et al., 2004). Moreover, the basal
level of neurogenesis in the subgranular layer of dentate gyrus was
decreased (Taupin et al., 2000; Pirttila et al., 2005) and the pro-
liferation and migration of newborn granule cells in the dentate
gyrus were impaired in CysC knockout mice (Pirttila et al., 2005),
supporting a role for CysC in neurogenesis. CysC was shown
to regulate glial development, as addition of human CysC into
the culture medium of primary brain cells increased the num-
ber of glial fibrillary acidic protein (GFAP)-positive and nestin-
positive cells, as well as the number of neurospheres formed from
embryonic brain (Hasegawa et al., 2007). Thus, another mech-
anism of neuroprotection by CysC might involve induction of
neurogenesis.
CONCLUSIONS
Immunohistochemical, genetic, and biochemical studies suggest
the involvement of CysC in AD. Immunohistochemical studies
have shown that CysC co-localizes with Aβ in amyloid-laden vas-
cular walls, and in senile plaque cores of amyloid and that CysC
and Aβ immunoreactivity co-localizes in a specific population
of pyramidal neurons that is vulnerable to neurodegeneration
in AD. Biochemical studies have shown binding of CysC to Aβ
and that this binding prevents Aβ oligomerization, fibril for-
mation, and amyloid deposition. Genetic studies have shown
linkage of a CysC gene polymorphism with AD, associated with
decreased secretion of CysC. Two FAD-linked presenilin 2 gene
mutations alter CysC trafficking and cause reduced CysC secre-
tion. Moreover, low concentrations of CysC were measured in
CSF and plasma of AD patients. While some studies have shown
that CysC can be toxic to cells under certain conditions, there are
reports showing that under other specific conditions, CysC can
be protective. While in high concentrations CysC may be toxic
to cells, low concentrations may not be sufficient to protect the
cells. We hypothesize that protection imparted by CysC is efficient
under a limited range of concentrations. Slightly increased CysC
expression activates multiple mechanisms of protection. These
mechanisms include inhibition of cysteine proteases, induction
of autophagy, induction of cell division, and prevention of amy-
loidogenesis. We hypothesize that in AD, a variety of these mech-
anisms are activated. However, the reduction in CysC levels may
represent the molecular factor responsible for increased risk of
AD. These finding propose that a therapy involving enhancing
CysC concentration may be developed to prevent, postpone, or
halt the disease.
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